Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS’ Plan To Fund Clinical Studies Seeks To Improve Data For Coverage Decisions

This article was originally published in The Pink Sheet Daily

Executive Summary

The Centers for Medicare & Medicaid Services’ move to cover carotid stent post-approval studies is in-line with recent Medicare trend to effectively promote data collection for national coverage determinations.

You may also be interested in...



Gambro Settles Medicare Billing Suit, Signs Corporate Integrity Agreement

The company will pay up to $355 mil. to settle a Medicare billing fraud civil suit initiated by the Department of Justice. Gambro is absolved of claims against a dialysis supply subsidiary in exchange for a guilty plea to a single felony charge.

FDA Dental Panel Will Consider BioMimetic PMA For Periodontal Diseases July 13

Sankyo Pharmaceuticals unit Luitpold has exclusive rights to distribute GEM 21S dental osseous defect therapy. BioMimetic expects European approval in the first half of 2005.

Boston Scientific To Study Complex Drug-Eluting Stent Use; Taxus Complaints Surface

The company is projecting worldwide Taxus revenue of $1.7 bil-$2.2 bil. for 2004, building on early 70% share claimed in the U.S. drug-eluting stent market. The paclitaxel-eluting stent's delivery platform has been subject to roughly 40 complaints since its launch in early March.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel